Sfoglia per Autore
Proteasome inhibitors: Bortezomib in multiple myeloma
2008 Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G.; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M.
Thalidomide maintenance in multiple myeloma: certainties and controversies.
2009 Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P.
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation
2009 Cavo M.; Zamagni E.; Tacchetti P.; Brioli A.; Pallotti C.; Pantani L.; Ceccolini M.; Petrucci A.; Testoni N.; Terragna C.; Marzocchi G.; Durante S.; Tosi P.; Baccarani M.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
2010 Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
2010 Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M.
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)
2011 Terragna, C ; Remondini, D; Durante, S; Martello, M; Patriarca, F; Levi, A; Pantani, L; Donnarumma, D ; Crippa, C; Bringhen, S; Rambaldi, A ; Offidani, M; Corradini, P; Narni, F; Fioritoni, G; Zaccaria, A; Baldini, L; Caravita, T; La Nasa, G; Cortelazzo, S; Martinelli, G; Baccarani, M; Cavo, M
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
2011 Zamagni E.; Brioli A.; Tacchetti P.; Zannetti B.; Pantani L.; Cavo M.
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
2011 Zamagni E.; Patriarca F.; Nanni C.; Zannetti B.; Englaro E.; Pezzi A.; Tacchetti P.; Buttignol S.; Perrone G.; Brioli A.; Pantani L.; Terragna C.; Carobolante F.; Baccarani M.; Fanin R.; Fanti S.; Cavo M.
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53
2011 TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNETTI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M
HIF 1 Alpha: A Suitable Target for Multiple Myeloma
2011 PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma
2012 Mancini; Elisa Leo; Elena Zamagni; Paola Tacchetti; Annamaria Brioli; Lucia Pantani; Beatrice Anna Zannetti; Giovanni Martinelli; Michele Cavo
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53
2012 Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Crippa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M.
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
2012 Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna C; Baccarani M; Cavo M.
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease.
2012 Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Baccarani M;Cavo M
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5
2012 Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli, A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.
2012 Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A.
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma
2013 Borsi, E; Perrone, G; Terragna, C; Martello, M; Mancini, M; Leo, E; Zamagni, E; Tacchetti, P; Brioli, A; Pantani, L; Zannetti, B; Martinelli, G; Cavo, M
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM).
2013 Terragna, Carolina; Remondini, Daniel; Martello, Marina; Pezzi, Annalisa; Patriarca, Francesca; Levi, Anna; Pantani, Lucia; Donnarumma, Daniela; Montanaro, Lorenzo; Crippa, Claudia; Bringhen, Sarah; Rambaldi, Alessandro; Offidani, Massimo; Corradini, Paolo; Narni, Franco; Fioritoni, Giuseppe; Zaccaria, Alfonso; Baldini, Luca; Caravita, Tommaso; La Nasa, Giorgio; Cortellazzo, Sergio; Martinelli, Giovanni; Cavo, Michele
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease.
2013 Martello, M; Terragna, C; Martinelli, G; Borsi, E; Zamagni, E; Pantani, L; Tacchetti, P; Zannetti, B; Mancuso, K; Dico, F; Cavo, M
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients
2013 Nanni C; Zamagni E; Celli M; Caroli P; Ambrosini V; Tacchetti P; Brioli A; Zannetti B; Pezzi A; Pantani L; Perrone G; Zompatori M; Cavo M; Colletti PM; Rubello D; Fanti S.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Proteasome inhibitors: Bortezomib in multiple myeloma | Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G....; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M. | 2008-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
| Thalidomide maintenance in multiple myeloma: certainties and controversies. | Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P. | 2009-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.04 Replica / breve intervento (e simili) | - |
| The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation | Cavo M.; Zamagni E.; Tacchetti P.; Brioli A.; Pallotti C.; Pantani L.; Ceccolini M.; Petrucci A.;... Testoni N.; Terragna C.; Marzocchi G.; Durante S.; Tosi P.; Baccarani M. | 2009-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
| Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. | Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamag...ni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M | 2010-01-01 | THE LANCET | - | 1.01 Articolo in rivista | - |
| Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. | Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucc...i A; Baccarani M; Cavo M. | 2010-01-01 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) | Terragna, C ; Remondini, D; Durante, S; Martello, M; Patriarca, F; Levi, A; Pantani, L; Donnarumm...a, D ; Crippa, C; Bringhen, S; Rambaldi, A ; Offidani, M; Corradini, P; Narni, F; Fioritoni, G; Zaccaria, A; Baldini, L; Caravita, T; La Nasa, G; Cortelazzo, S; Martinelli, G; Baccarani, M; Cavo, M | 2011-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. | Zamagni E.; Brioli A.; Tacchetti P.; Zannetti B.; Pantani L.; Cavo M. | 2011-01-01 | SEMINARS IN THROMBOSIS AND HEMOSTASIS | - | 1.01 Articolo in rivista | - |
| Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation | Zamagni E.; Patriarca F.; Nanni C.; Zannetti B.; Englaro E.; Pezzi A.; Tacchetti P.; Buttignol S....; Perrone G.; Brioli A.; Pantani L.; Terragna C.; Carobolante F.; Baccarani M.; Fanin R.; Fanti S.; Cavo M. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 | TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNET...TI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| HIF 1 Alpha: A Suitable Target for Multiple Myeloma | PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI ...P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma | Mancini; Elisa Leo; Elena Zamagni; Paola Tacchetti; Annamaria Brioli; Lucia Pantani; Beatrice Ann...a Zannetti; Giovanni Martinelli; Michele Cavo | 2012-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 | Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Cri...ppa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M. | 2012-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. | Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna ...C; Baccarani M; Cavo M. | 2012-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. | Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Bacca...rani M;Cavo M | 2012-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 | Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli..., A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M. | 2012-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. | Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perr...one G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A. | 2012-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma | Borsi, E; Perrone, G; Terragna, C; Martello, M; Mancini, M; Leo, E; Zamagni, E; Tacchetti, P; Bri...oli, A; Pantani, L; Zannetti, B; Martinelli, G; Cavo, M | 2013-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). | Terragna, Carolina; Remondini, Daniel; Martello, Marina; Pezzi, Annalisa; Patriarca, Francesca; L...evi, Anna; Pantani, Lucia; Donnarumma, Daniela; Montanaro, Lorenzo; Crippa, Claudia; Bringhen, Sarah; Rambaldi, Alessandro; Offidani, Massimo; Corradini, Paolo; Narni, Franco; Fioritoni, Giuseppe; Zaccaria, Alfonso; Baldini, Luca; Caravita, Tommaso; La Nasa, Giorgio; Cortellazzo, Sergio; Martinelli, Giovanni; Cavo, Michele | 2013-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. | Martello, M; Terragna, C; Martinelli, G; Borsi, E; Zamagni, E; Pantani, L; Tacchetti, P; Zannetti..., B; Mancuso, K; Dico, F; Cavo, M | 2013-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients | Nanni C; Zamagni E; Celli M; Caroli P; Ambrosini V; Tacchetti P; Brioli A; Zannetti B; Pezzi A; P...antani L; Perrone G; Zompatori M; Cavo M; Colletti PM; Rubello D; Fanti S. | 2013-01-01 | CLINICAL NUCLEAR MEDICINE | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile